{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017185","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.508925+00:00","generated_at":"2026-06-22T00:34:35.673974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phibro Q1 net income down 41% to $3.9M; lowers FY2023 EPS guidance due to rates, tax","bullets":["Q1 net sales $232.5M (+8% YoY); diluted EPS $0.10 (-41%); adjusted diluted EPS $0.21 (-18%).","Animal Health segment sales $154.9M (+10%); Mineral Nutrition $59.6M (+10%).","FY2023 guidance: net sales $960M-$1B and adjusted EBITDA $113-$118M (unchanged).","FY2023 diluted EPS guidance cut to $0.96-$1.06 from $1.11-$1.21; adjusted EPS to $1.21-$1.31 from $1.28-$1.38.","Adjusted effective tax rate guidance raised to 33% from 30% due to foreign tax credit regulations."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017185","json":"https://secwatch.observer/filing/0001558370-22-017185.json","markdown":"https://secwatch.observer/filing/0001558370-22-017185.md","text":"https://secwatch.observer/filing/0001558370-22-017185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837022017185/0001558370-22-017185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837022017185/pahc-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:34:35.673974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"086e1fc5a248f119476883005f11f8dd39ffdd26","claim":"PHIBRO ANIMAL HEALTH CORP reported first quarter ended September 30, 2022 results: revenue $232.5 million, net income $3.9 million, EPS $0.10.","evidence_excerpt":"tax rate for the year ending June 30, 2023. ​ Highlights for the three months ended September 30, 2022 (compared to the three months ended September 30, 2021) ​ - Net sales of $232.5 million, an increase of $17.9 million, or 8% - Net income of $3.9 million, a decrease of $2.7 million, or 41% - Diluted EPS of $0.10, a decrease of $0.07, or 41% - Adjusted EBITDA of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837022017185/0001558370-22-017185-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended September 30, 2022"},{"label":"Revenue","value":"$232.5 million"},{"label":"Net income","value":"$3.9 million"},{"label":"EPS","value":"$0.10"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}